PAINWeek 2017

Multiple new drugs for pain management have been recently introduced or approved, and additional agents are currently under investigation.

Dr Zacharoff provided advice for clinicians dealing with fluid guidelines and constraints regarding opioid prescribing.

In patients with concomitant fibromyalgia and PTSD, opioid therapy was shown to improve quality of life and help patients return to a greater sense of “normalcy.”

Opioid treatment of acute postoperative pain was shown to cause high rates of postoperative nausea and vomiting, particularly in women and younger patients.

Compared with placebo, data for the 3mg, 6mg, and combined active doxepin treatment groups significantly improved all PSG and subjective evaluated sleep outcomes for all days and nights up to Night 30.

Dr Gould covered the risks of co-prescribing benzodiazepines and opioids, particularly for elderly patients, and proposed therapeutic alternatives at PAINWeek 2017.

The researchers presented examined the effects of 66mg intact oral morphine ARER, 60mg crushed intranasal morphine ARER, 60mg crushed intranasal morphine ER, 30mg intact oral oxycodone ARIR, 30mg crushed intranasal oxycodone ARIR, and 30mg crushed intranasal IR oxycodone or placebo among nondependent recreational opioid users.

At PAINWeek 2017, the president of the National Association of Drug Diversion Investigators discussed ways to balance pain management needs and overdose prevention measures.

In patients with opioid-induced constipation, naldemedine was shown to improve patient assessment of symptoms and quality of life.

Results of the study found that only 4% of H only patients used triptan medications compared to 46-50% of patients in the other 4 groups.